Prevalence and incidence of intra- and extrahepatic complications of NAFLD in patients with type 2 diabetes mellitus

Abstract

Nonalcoholic fatty liver disease (NAFLD) is linked to abdominal obesity, insulin resistance and type 2 diabetes mellitus (T2DM). The association of NAFLD with T2DM is bidirectional. In fact, evidence suggests that abdominal obesity, T2DM and metabolic syndrome play a part in the development and progression of NAFLD. Alternatively, NAFLD is associated with an increased risk of having T2DM and metabolic syndrome. According to this background, it is unsurprising that patients with T2DM patients also have a higher prevalence of NAFLD than those with no T2DM, as well as an increased risk of developing liver-related and extrahepatic complications, mainly cardiovascular and renal diseases. Seeing the relationship of NAFLD with insulin resistance, obesity and T2DM, recent consensus proposes a change in nomenclature from NAFLD to metabolic associated fatty liver disease. In this review, we will discuss the prevalence and incidence of NAFLD (as detected by imaging techniques or liver biopsy) in patients with type T2DM with particular regard to hepatic and extrahepatic complications.

Keywords

Nonalcoholic fatty liver disease / NASH / metabolic associated fatty liver disease / diabetes / type 2 diabetes

References

[1] Mantovani A,Mosca A,Byrne CD.Complications, morbidity and mortality of nonalcoholic fatty liver disease..Metabolism2020;111S:154170

[2] Targher G,Byrne CD.Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus..Nat Rev Endocrinol2018;14:99-114

[3] Lonardo A,Lugari S.Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity..Ann Hepatol2020;19:359-66

[4] Lonardo A,Mantovani A.Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?.J Hepatol2018;68:335-52

[5] Ortiz-Lopez C,Orsak B.Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD)..Diabetes Care2012;35:873-8 PMCID:PMC3308295

[6] Williams KH,Gorrell MD,Twigg SM.Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo..Endocr Rev2013;34:84-129

[7] Targher G,Byrne CD.Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?.Diabetes Metab2016;42:142-56

[8] Adams LA,Tilg H.Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases..Gut2017;66:1138-53

[9] Eslam M,George J.MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease..Gastroenterology2020;158:1999-2014.e1

[10] Tilg H.From NAFLD to MAFLD: when pathophysiology succeeds..Nat Rev Gastroenterol Hepatol2020;17:387-8

[11] Fouad Y,Bollipo S,Ajlouni Y.What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’..Liver Int2020;40:1254-61

[12] Portillo-Sanchez P,Maximos M.High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels..J Clin Endocrinol Metab2015;100:2231-8 PMCID:PMC6287506

[13] Kwok R,Wong GL.Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study..Gut2016;65:1359-68

[14] Arab JP,Gallego C.High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients..Ann Hepatol2016;15:721-8

[15] Jung CH,Choi DH.Association of grade of non-alcoholic fatty liver disease and glycated albumin to glycated hemoglobin ratio in patients with type 2 diabetes mellitus..Diabetes Res Clin Pract2017;125:53-61

[16] Masarone M,Aglitti A.Liver biopsy in type 2 diabetes mellitus: Steatohepatitis represents the sole feature of liver damage..PLoS One2017;12:e0178473 PMCID:PMC5453539

[17] Petit JM,Guiu B.Type 1 diabetes is not associated with an increased prevalence of hepatic steatosis..Diabet Med2015;32:1648-51

[18] Wilman HR,Garratt S.Characterisation of liver fat in the UK Biobank cohort..PLoS One2017;12:e0172921 PMCID:PMC5328634

[19] Doycheva I,Nguyen P.Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE..Aliment Pharmacol Ther2016;43:83-95 PMCID:PMC4673036

[20] Ding X,Wang Y.Nonalcoholic fatty liver disease and associated metabolic risks of hypertension in type 2 diabetes: a cross-sectional community-based study..Int J Endocrinol2017;2017:5262560 PMCID:PMC5385250

[21] Al Rifai M,Nasir K.The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis (MESA)..Atherosclerosis2015;239:629-33 PMCID:PMC4406399

[22] Williams KH,Constantino M.An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes..J Diabetes Complications2015;29:1240-7

[23] Cusi K,Zhang S.Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes..Diabetes Obes Metab2017;19:1630-4

[24] Guo K,Lu J.Non-alcoholic fatty liver disease is associated with late but not early atherosclerotic lesions in Chinese inpatients with type 2 diabetes..J Diabetes Complications2017;31:80-5

[25] Herath HMM,Weerarathna TP.Prevalence and associations of non-alcoholic fatty liver disease (NAFLD) in Sri Lankan patients with type 2 diabetes: A single center study..Diabetes Metab Syndr2019;13:246-50

[26] Sberna AL,Rouland A.European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) clinical practice recommendations for the management of non-alcoholic fatty liver disease: evaluation of their application in people with Type 2 diabetes..Diabet Med2018;35:368-75

[27] Krishan S.Correlation between non-alcoholic fatty liver disease (NAFLD) and dyslipidemia in type 2 diabetes..Diabetes Metab Syndr2016;10:S77-81

[28] Su X,Zheng C.The relationship between non-alcoholic fatty liver and skeletal muscle mass to visceral fat area ratio in women with type 2 diabetes..BMC Endocr Disord2019;19:76 PMCID:PMC6637487

[29] Vanjiappan S,Ananthakrishnan R,Mehalingam V.Nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and its association with cardiovascular disease..Diabetes Metab Syndr2018;12:479-82

[30] He X,Ma X.The association of serum FGF23 and non-alcoholic fatty liver disease is independent of vitamin D in type 2 diabetes patients..Clin Exp Pharmacol Physiol2018;45:668-74

[31] Kabir MA,Siddiqui NI.Prevalence of non-alcoholic fatty liver disease and its biochemical predictors in patients with type-2 diabetes mellitus..Mymensingh Med J2018;27:237-44

[32] Lai LL,Vethakkan SR,Mahadeva S.Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography..J Gastroenterol Hepatol2019;34:1396-403

[33] Hashimoto Y,Fukuda T,Yamazaki M.The relationship between hepatic steatosis and skeletal muscle mass index in men with type 2 diabetes..Endocr J2016;63:877-84

[34] Zou Y,Wang C.Association between non-alcoholic fatty liver disease and peripheral artery disease in patients with type 2 diabetes..Intern Med J2017;47:1147-53

[35] Afolabi BI,Ikem RT,Idowu BM.The relationship between glycaemic control and non-alcoholic fatty liver disease in nigerian type 2 diabetic patients..J Natl Med Assoc2018;110:256-64

[36] Moh Moh MA,Lee B.Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus..Diab Vasc Dis Res2019;16:186-95

[37] Cosma A,Gaiani S.Clinical and biochemical determinants of the extent of liver steatosis in type 2 diabetes mellitus..Eur J Gastroenterol Hepatol2015;27:1386-91

[38] Almobarak AO,Suliman EA.Prevalence of and predictive factors for nonalcoholic fatty liver disease in Sudanese individuals with type 2 diabetes: Is metabolic syndrome the culprit?.Arab J Gastroenterol2015;16:54-8

[39] Yan LH,Guan Y.Assessment of the relationship between non-alcoholic fatty liver disease and diabetic complications..J Diabetes Investig2016;7:889-94 PMCID:PMC5089952

[40] Alsabaani AA,Awadalla NJ,Al Humayed SM.Non-Alcoholic fatty liver disease among type-2 diabetes mellitus patients in abha city, south western saudi arabia..Int J Environ Res Public Health2018;15:2521 PMCID:PMC6266142

[41] Gutierrez-Buey G,Llavero-Valero M,Salvador J.Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?.Eur J Intern Med2017;41:74-8

[42] Zawdie B,Wolide AD,Bobasa EM.Non-alcoholic fatty liver disease and associated factors among type 2 diabetic patients in southwest ethiopia..Ethiop J Health Sci2018;28:19-30 PMCID:PMC5866286

[43] Dvorak K,Petrtyl J.The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic..Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub2015;159:442-8

[44] Hua X,Pan F,Cui W.Non-alcoholic fatty liver disease is an influencing factor for the association of SHBG with metabolic syndrome in diabetes patients..Sci Rep2017;7:14532 PMCID:PMC5674048

[45] Mantovani A,Bergamini C.Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes..PLoS One2015;10:e0135329 PMCID:PMC4529087

[46] Olusanya TO,Adeyomoye AA.Non alcoholic fatty liver disease in a Nigerian population with type II diabetes mellitus..Pan Afr Med J2016;24:20 PMCID:PMC4992392

[47] Chang W,Sun L,Li Y.Evaluation of left atrial function in type 2 diabetes mellitus patients with nonalcoholic fatty liver disease by two-dimensional speckle tracking echocardiography..Echocardiography2019;36:1290-7

[48] Zhao CC,Li LX.Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes..J Diabetes Complications2016;30:1074-80

[49] Zhang J,Cheng Y.Low serum CTRP3 levels are associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus..Cytokine2018;106:131-5

[50] Johansen ML,Rasmussen J.Low N-terminal pro-brain natriuretic peptide levels are associated with non-alcoholic fatty liver disease in patients with type 2 diabetes..Diabetes Metab2019;45:429-35

[51] Fan N,Xia Z,Wang Y.Sex-specific association between serum uric acid and nonalcoholic fatty liver disease in type 2 diabetic patients..J Diabetes Res2016;2016:3805372 PMCID:PMC4921134

[52] García Díaz E,Gutiérrez V.Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study..Endocrinol Nutr2016;63:194-201

[53] Demir M,Yılmaz Y.Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study..Turk J Gastroenterol2019;30:266-70 PMCID:PMC6428511

[54] Petit JM,Guiu B.GCKR polymorphism influences liver fat content in patients with type 2 diabetes..Acta Diabetol2016;53:237-42

[55] Zhao H,Li Z.Risk factors associated with nonalcohol fatty liver disease and fibrosis among patients with type 2 diabetes mellitus..Medicine (Baltimore)2018;97:e12356 PMCID:PMC6156034

[56] Mantovani A,Bonapace S.Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour holter monitoring..Diabetes Care2016;39:1416-23

[57] Barchetta I,De Gioannis R.Procollagen-III peptide identifies adipose tissue-associated inflammation in type 2 diabetes with or without nonalcoholic liver disease..Diabetes Metab Res Rev2018;34:e2998

[58] Choe EY,Choi YJ.Waist-to-calf circumstance ratio is an independent predictor of hepatic steatosis and fibrosis in patients with type 2 diabetes..J Gastroenterol Hepatol2018;33:1082-91

[59] Silaghi CA,Crăciun AE.Age, abdominal obesity, and glycated hemoglobin are associated with carotid atherosclerosis in type 2 diabetes patients with nonalcoholic fatty liver disease..Med Ultrason2015;17:300-7

[60] Lee H,Choi YJ.Association between non-alcoholic steatohepatitis and left ventricular diastolic dysfunction in type 2 diabetes mellitus..Diabetes Metab J2020;44:267-76 PMCID:PMC7188976

[61] Seo DH,Park SW.Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes..Diabetes Metab2020;46:362-9

[62] Yeung MW,Choi KC.Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes..J Hepatol2017;147-56

[63] Bellan M,Barbaglia MN.Severity of nonalcoholic fatty liver disease in type 2 diabetes mellitus: relationship between nongenetic factors and PNPLA3/HSD17B13 polymorphisms..Diabetes Metab J2019;43:700-10 PMCID:PMC6834828

[64] Tuong TTK,Phu PQT,Dinh TC.Non-alcoholic fatty liver disease in patients with type 2 diabetes: evaluation of hepatic fibrosis and steatosis using fibroscan..Diagnostics (Basel)2020;10:159 PMCID:PMC7151057

[65] Mantovani A,Lando MG.Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes..Diabetes Metab2020;46:296-303

[66] Choi DH,Mok JO,Kang SK.Nonalcoholic fatty liver disease and abdominal fat accumulation according to vitamin d status in patients with type 2 diabetes..J Obes Metab Syndr2018;27:53-60 PMCID:PMC6489485

[67] Heidari Z.Prevalence of non alcoholic fatty liver disease and its association with diabetic nephropathy in patients with type 2 diabetes mellitus..J Clin Diagn Res2017;11:OC04-7 PMCID:PMC5483726

[68] Mandal A,Kafle P.Elevated liver enzymes in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease..Cureus2018;10:e3626 PMCID:PMC6347442

[69] Motta BM,Gögele M.Microbiota, type 2 diabetes and non-alcoholic fatty liver disease: protocol of an observational study..J Transl Med2019;17:408 PMCID:PMC6891972

[70] Sporea I,Popescu A.Screening for liver fibrosis and steatosis in a large cohort of patients with type 2 diabetes using vibration controlled transient elastography and controlled attenuation parameter in a single-center real-life experience..J Clin Med2020;9:1032 PMCID:PMC7230646

[71] Lombardi R,Targher G.Liver fibrosis by FibroScan^® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes..Liver Int2020;40:347-54

[72] Hamid S,Sharif F.Nonalcoholic fatty liver diseases among recently diagnosed patients with diabetes mellitus and risk factors..Euroasian J Hepatogastroenterol2019;9:9-13 PMCID:PMC6969327

[73] Lee YJ,Hung WC.Common and unique factors and the bidirectional relationship between chronic kidney disease and nonalcoholic fatty liver in type 2 diabetes patients..Diabetes Metab Syndr Obes2020;13:1203-14 PMCID:PMC7173841

[74] El-Ashmawy HM.Serum fetuin-B level is an independent marker for nonalcoholic fatty liver disease in patients with type 2 diabetes..Eur J Gastroenterol Hepatol2019;31:859-64

[75] Mangla N,Caussy C.Liver stiffness severity is associated with increased cardiovascular risk in patients with type 2 diabetes..Clin Gastroenterol Hepatol2020;18:744-6.e1 PMCID:PMC6984972

[76] Byrne CD,Scorletti E.Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults..BMJ2018;362:k2734

[77] Wang CC,Hsieh TC.Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk..Kaohsiung J Med Sci2012;28:151-60

[78] Chen K,Quah JH.Clinical spectrum of non-alcoholic fatty liver disease in patients with diabetes mellitus..PLoS One2020;15:e0236977 PMCID:PMC7446805

[79] Gerber L,Mishra A.Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study..Aliment Pharmacol Ther2012;36:772-81

[80] Zelber-Sagi S,Mlynarsky L.The mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms..Liver Int2017;37:936-49

[81] Eslam M,Romeo S.Genetics and epigenetics of NAFLD and NASH: clinical impact..J Hepatol2018;68:268-79

[82] Bazick J,Neuschwander-Tetri BA.Clinical model for NASH and advanced fibrosis in adult patients with diabetes and NAFLD: guidelines for referral in NAFLD..Diabetes Care2015;38:1347-55 PMCID:PMC4477334

[83] McPherson S,Henderson E,Day CP.Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management..J Hepatol2015;62:1148-55

[84] Loomba R,Unalp A.Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis..Hepatology2012;56:943-51 PMCID:PMC3407289

[85] Puchakayala BK,Kanwar P,Sanivarapu RR.Histopathological differences utilizing the nonalcoholic fatty liver disease activity score criteria in diabetic (type 2 diabetes mellitus) and non-diabetic patients with nonalcoholic fatty liver disease..World J Hepatol2015;7:2610-8 PMCID:PMC4635147

[86] Younossi ZM,de Avila L.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis..J Hepatol2019;71:793-801

[87] Targher G.Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications..J Clin Endocrinol Metab2013;98:483-95

[88] Okamoto M,Yoda Y,Fujino MA.The association of fatty liver and diabetes risk..J Epidemiol2003;13:15-21

[89] Shibata M,Taguchi M,Otsuki M.Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men..Diabetes Care2007;30:2940-4

[90] Kim CH,Lee KU,Kim HK.Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults..Diabet Med2008;25:476-81

[91] Bae JC,Lee WY.Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study..Diabetes Care2011;34:727-9 PMCID:PMC3041216

[92] Park SK,Shin HC.Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study..Hepatology2013;57:1378-83

[93] Sung KC,Wild SH.Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes..Diabetes Care2012;35:717-22 PMCID:PMC3308286

[94] Kasturiratne A,Dassanayake AS.Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus..J Gastroenterol Hepatol2013;28:142-7

[95] Chang Y,Yun KE,Cho YK.Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population..Am J Gastroenterol2013;108:1861-8

[96] Choi JH,Bae JC.Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: a 4-year longitudinal study..Arch Med Res2013;44:115-20

[97] Yamazaki H,Tsuji K,Maguchi H.Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes..Diabetes Care2015;38:1673-9

[98] Ming J,Gao B.Non-alcoholic fatty liver disease predicts type 2 diabetes mellitus, but not prediabetes, in Xi’an, China: a five-year cohort study..Liver Int2015;35:2401-7

[99] Li WD,Li GM.Comparison of effects of obesity and non-alcoholic fatty liver disease on incidence of type 2 diabetes mellitus..World J Gastroenterol2015;21:9607-13 PMCID:PMC4548121

[100] Shah RV,Lima JA.Liver fat, statin use, and incident diabetes: The Multi-ethnic study of atherosclerosis..Atherosclerosis2015;242:211-7 PMCID:PMC4546884

[101] Fukuda T,Kojima T.The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals..Liver Int2016;36:275-83

[102] Chen GY,Li F.New risk-scoring system including non-alcoholic fatty liver disease for predicting incident type 2 diabetes in East China: Shanghai Baosteel Cohort..J Diabetes Investig2016;7:206-11 PMCID:PMC4773660

[103] Li Y,Tang Y.Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: Evidence from the Dongfeng-Tongji cohort study..PLoS One2017;12:e0174291 PMCID:PMC5369778

[104] Ma J,Pedley A.Bi-directional analysis between fatty liver and cardiovascular disease risk factors..J Hepatol2017;66:390-7 PMCID:PMC5250546

[105] Chen SC,Jhao JY,Tsao CK.Liver fat, hepatic enzymes, alkaline phosphatase and the risk of incident type 2 diabetes: a prospective study of 132,377 adults..Sci Rep2017;7:4649 PMCID:PMC5498613

[106] Liu M,Zeng J,He Y.Association of NAFLD with diabetes and the impact of BMI changes: a 5-year cohort study based on 18,507 elderly..J Clin Endocrinol Metab2017;102:1309-16

[107] Mantovani A,Bonora E.Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis..Diabetes Care2018;41:372-82

[108] Mantovani A,Beatrice G,Byrne CD.Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals..Gut2020;gutjnl-2020-322572

[109] Sung KC,Byrne CD.Resolution of fatty liver and risk of incident diabetes..J Clin Endocrinol Metab2013;98:3637-43

[110] Cho HJ,Park JI.Improvement of nonalcoholic fatty liver disease reduces the risk of type 2 diabetes mellitus..Gut Liver2019;13:440-9 PMCID:PMC6622569

[111] Heo NY.Nonalcoholic fatty liver disease is a stepping stone in the path toward diabetes mellitus..Gut Liver2019;13:383-4 PMCID:PMC6622571

[112] Mauvais-jarvis F,Barnes PJ.Sex and gender: modifiers of health, disease, and medicine..Lancet2020;396:565-82 PMCID:PMC7440877

[113] Lonardo A,Ballestri S.Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps..Hepatology2019;70:1457-69 PMCID:PMC6766425

[114] Rinella ME.Nonalcoholic fatty liver disease: a systematic review..JAMA2015;313:2263-73

[115] de Marco R,Zoppini G,Bonora E.Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study..Diabetes Care1999;22:756-61

[116] Zoppini G,Gennaro N,Targher G.Mortality from chronic liver diseases in diabetes..Am J Gastroenterol2014;109:1020-5

[117] Adams LA,St Sauver JL.Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study..Am J Gastroenterol2010;105:1567-73 PMCID:PMC2898908

[118] Elkrief L,Sarin S,Paradis V.Diabetes mellitus in patients with cirrhosis: clinical implications and management..Liver Int2016;36:936-48

[119] Bertot LC,de Boer B.Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease..Liver Int2018;38:1793-802

[120] de Lédinghen V,Gonzalez C.Screening for liver fibrosis by using FibroScan(®) and FibroTest in patients with diabetes..Dig Liver Dis2012;44:413-8

[121] Sanyal A,Moyneur E.Population-based risk factors and resource utilization for HCC: US perspective..Curr Med Res Opin2010;26:2183-91

[122] Ertle J,Sowa JP.Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis..Int J Cancer2011;128:2436-43

[123] Targher G,Padovani R.Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients..Diabetes Care2007;30:1212-8

[124] Cassidy S,Thoma C.Cardiac structure and function are altered in type 2 diabetes and non-alcoholic fatty liver disease and associate with glycemic control..Cardiovasc Diabetol2015;14:23 PMCID:PMC4330943

[125] Mantovani A,Bergamini C.Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease..Metabolism2015;64:879-87

[126] Targher G,Bonapace S.Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes..Nutr Metab Cardiovasc Dis2014;24:663-9

[127] Mantovani A,Pichiri I.Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus..PLoS One2017;12:e0185459 PMCID:PMC5628831

[128] Polyzos SA.Making progress in nonalcoholic fatty liver disease (NAFLD) as we are transitioning from the era of NAFLD to dys-metabolism associated fatty liver disease (DAFLD)..Metabolism2020;111S:154318 PMCID:PMC7372254

[129] Mantovani A.Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease..Ann Transl Med2017;5:270 PMCID:PMC5515814

[130] Wang P,Cao W,Liu Z.Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis..Diabetes Metab Res Rev2012;28:109-22

[131] Yang WS,Bray F.The role of pre-existing diabetes mellitus on hepatocellular carcinoma occurrence and prognosis: a meta-analysis of prospective cohort studies..PLoS One2011;6:e27326 PMCID:PMC3244388

[132] Petrick JL,Zeleniuch-Jacquotte A.Body mass index, diabetes and intrahepatic cholangiocarcinoma risk: the liver cancer pooling project and meta-analysis..Am J Gastroenterol2018;113:1494-505 PMCID:PMC6521884

[133] Huang YJ,Chiou HY.Interactive role of diabetes mellitus and female sex in the risk of cholangiocarcinoma: a population-based nested case-control study..Oncotarget2017;8:6642-51 PMCID:PMC5351659

[134] Anstee QM,Tilg H.Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease..Nat Rev Gastroenterol Hepatol2018;15:425-39

[135] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes..Hepatology2016;64:73-84

[136] Paik JM,De Avila L,Racila A.Mortality related to nonalcoholic fatty liver disease is increasing in the United States..Hepatol Commun2019;3:1459-71 PMCID:PMC6824058

[137] Targher G,Lonardo A,Barbui C.Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis..J Hepatol2016;65:589-600

[138] Meyersohn NM,Corey KE.Association of hepatic steatosis with major adverse cardiovascular events, independent of coronary artery disease..Clin Gastroenterol Hepatol2020;S1542-3565(20)30992-7

[139] Mantovani A,Targher G,Bonora E.Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals..J Endocrinol Invest2012;35:215-8

[140] Rossi A,Zoppini G.Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes..Diabetes Care2012;35:1781-6 PMCID:PMC3402245

[141] Mantovani A,Sandri D.Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis..Liver Int2019;39:758-69

[142] Mantovani A.Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis..J Clin Transl Hepatol2017;5:134-41 PMCID:PMC5472934

[143] Chalasani N,Lavine JE.The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases..Hepatology2018;67:328-57

[144] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease..J Hepatol2016;64:1388-402

[145] Byrne CD.NAFLD as a driver of chronic kidney disease..J Hepatol2020;72:785-801

[146] Jia G,Wang Q.Non-Alcoholic fatty liver disease is a risk factor for the development of diabetic nephropathy in patients with type 2 diabetes mellitus..PLoS One2015;10:e0142808 PMCID:PMC4643958

[147] Nampoothiri RV,Rathi M.Renal dysfunction in patients with nonalcoholic fatty liver disease is related to the presence of diabetes mellitus and severity of liver disease..J Clin Exp Hepatol2019;9:22-8 PMCID:PMC6363960

[148] Mantovani A,Dalbeni A,Buzzetti E.Risk of kidney dysfunction in NAFLD..Curr Pharm Des2020;26:1045-61

[149] Targher G,Bertolini L.Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease..J Am Soc Nephrol2008;19:1564-70 PMCID:PMC2488256

[150] Mantovani A,Byrne CD.Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis..Metabolism2018;79:64-76

[151] Paik J,Younoszai Z,Trimble G.Chronic kidney disease is independently associated with increased mortality in patients with nonalcoholic fatty liver disease..Liver Int2019;39:342-52

[152] Önnerhag K,Nilsson PM.Increased mortality in non-alcoholic fatty liver disease with chronic kidney disease is explained by metabolic comorbidities..Clin Res Hepatol Gastroenterol2019;43:542-50

[153] Mantovani A,Zusi C.PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings..Liver Int2020;40:1130-41

[154] Lv WS,Gao YY.Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes..World J Gastroenterol2013;19:3134-42 PMCID:PMC3662955

[155] Kim BY,Mok JO,Kim CH.Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease..J Diabetes Investig2014;5:170-5 PMCID:PMC4023580

[156] Asrih M.Metabolic syndrome and nonalcoholic fatty liver disease: is insulin resistance the link?.Mol Cell Endocrinol.2015;418 Pt 1:55-65

[157] Miele L,La Torre G.Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease..Hepatology2009;49:1877-87

[158] Beserra BT,do Rosario VA,Kuntz MG.A systematic review and meta-analysis of the prebiotics and synbiotics effects on glycaemia, insulin concentrations and lipid parameters in adult patients with overweight or obesity..Clin Nutr2015;34:845-58

[159] Randrianarisoa E,Wang X.Relationship of serum trimethylamine N-oxide (TMAO) levels with early atherosclerosis in humans..Sci Rep2016;6:26745 PMCID:PMC4882652

[160] Khurana S,Pallone TL.Bile acids regulate cardiovascular function..Clin Transl Sci2011;4:210-8 PMCID:PMC3705909

[161] Semenkovich CF.Insulin resistance and atherosclerosis..J Clin Invest2006;116:1813-22 PMCID:PMC1483180

[162] Malehmir M,Gallage S.Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer..Nat Med2019;25:641-55